Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma
Purpose: Symptom management is an integral component of care for patients with renal cell carcinoma (RCC). We evaluated the efficacy of radiation therapy (RT) and factors influencing symptom in an ethnically diverse patient population. Methods and Materials: An institutional review board-approved re...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-10-01
|
| Series: | Advances in Radiation Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452109425001575 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226962598363136 |
|---|---|
| author | Young Suk Kwon, MD, MPH Eric Hsu, MD, PhD Maggie Stein, BSPH Alana Christie, MS Aurelie Garant, MD Neil B. Desai, MD Andrew Wang, MD Daniel X. Yang, MD Allen Yen, MD Mihailo Miljanic, MD Kevin D. Courtney, MD, PhD Hans Hammers, MD, PhD Tian Zhang, MD Waddah Arafat, MD Qian Qin, MD Suzanne Cole, MD James Brugarolas, MD, PhD Robert Timmerman, MD Raquibul Hannan, MD, PhD |
| author_facet | Young Suk Kwon, MD, MPH Eric Hsu, MD, PhD Maggie Stein, BSPH Alana Christie, MS Aurelie Garant, MD Neil B. Desai, MD Andrew Wang, MD Daniel X. Yang, MD Allen Yen, MD Mihailo Miljanic, MD Kevin D. Courtney, MD, PhD Hans Hammers, MD, PhD Tian Zhang, MD Waddah Arafat, MD Qian Qin, MD Suzanne Cole, MD James Brugarolas, MD, PhD Robert Timmerman, MD Raquibul Hannan, MD, PhD |
| author_sort | Young Suk Kwon, MD, MPH |
| collection | DOAJ |
| description | Purpose: Symptom management is an integral component of care for patients with renal cell carcinoma (RCC). We evaluated the efficacy of radiation therapy (RT) and factors influencing symptom in an ethnically diverse patient population. Methods and Materials: An institutional review board-approved retrospective review was conducted of patients with symptomatic extracranial RCC metastases treated with RT between 2011 and 2022 at a tertiary referral center. Symptoms were categorized as pain, neurologic (paresthesia or weakness), respiratory (dyspnea, hemoptysis, or cough) and gastrointestinal/genitourinary (GI/GU) bleeding. Time to symptom alleviation was measured from the start of RT and assessed during-treatment and follow-up visits. Descriptive and survival analyses were performed. Associations between symptom relief and treatment parameters were evaluated by generalized estimating equations Results: We identified 240 symptomatic RCC patients who received RT to 581 metastases including 93.0% for pain, 4.0% for neurologic, 4.1% for respiratory, and 1.6% for GI/GU bleeding. Symptom improvement was observed in 84.0% of patients overall at 6 months (95% confidence interval [CI], 80.4-87.2%). Among symptom categories, pain improved in 84.6% (95% CI, 81.0-87.9%) at 6 months, respiratory symptoms in 69.9% (49.3-88.0%) at 6 months, neurologic symptoms in 88.6% (69.6-98.1%) at 6 months, and GI/GU bleeding in 37.5% (13.9-77.1%) at 1 month. The median times to overall and pain alleviation were 1.6 months (range, 1.4-1.9) and 1.6 months (range, 1.4-1.9), respectively. Although the odds of achieving pain palliation were similar between stereotactic and conventional RT, unexpectedly, symptom relief occurred more quickly with conventional RT (P < .001). Conclusions: Stereotactic and conventional RT are effective for symptom palliation for patients with metastatic RCC. |
| format | Article |
| id | doaj-art-c95b7e2d494349d784f21e935f97e895 |
| institution | Kabale University |
| issn | 2452-1094 |
| language | English |
| publishDate | 2025-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Advances in Radiation Oncology |
| spelling | doaj-art-c95b7e2d494349d784f21e935f97e8952025-08-24T05:13:34ZengElsevierAdvances in Radiation Oncology2452-10942025-10-01101010187010.1016/j.adro.2025.101870Extracranial Palliative Radiation Therapy for Renal Cell CarcinomaYoung Suk Kwon, MD, MPH0Eric Hsu, MD, PhD1Maggie Stein, BSPH2Alana Christie, MS3Aurelie Garant, MD4Neil B. Desai, MD5Andrew Wang, MD6Daniel X. Yang, MD7Allen Yen, MD8Mihailo Miljanic, MD9Kevin D. Courtney, MD, PhD10Hans Hammers, MD, PhD11Tian Zhang, MD12Waddah Arafat, MD13Qian Qin, MD14Suzanne Cole, MD15James Brugarolas, MD, PhD16Robert Timmerman, MD17Raquibul Hannan, MD, PhD18Department of Radiation Oncology, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Radiation Oncology, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Radiation Oncology, University of Texas, Southwestern Medical Center, Dallas, TexasKidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Radiation Oncology, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Radiation Oncology, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Radiation Oncology, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Radiation Oncology, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Radiation Oncology, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Radiation Oncology, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Internal Medicine, Hematology Oncology, University of Texas, Southwestern Medical Center, Dallas, Texas; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Internal Medicine, Hematology Oncology, University of Texas, Southwestern Medical Center, Dallas, Texas; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Internal Medicine, Hematology Oncology, University of Texas, Southwestern Medical Center, Dallas, Texas; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Internal Medicine, Hematology Oncology, University of Texas, Southwestern Medical Center, Dallas, Texas; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Internal Medicine, Hematology Oncology, University of Texas, Southwestern Medical Center, Dallas, Texas; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Internal Medicine, Hematology Oncology, University of Texas, Southwestern Medical Center, Dallas, Texas; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Internal Medicine, Hematology Oncology, University of Texas, Southwestern Medical Center, Dallas, Texas; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Radiation Oncology, University of Texas, Southwestern Medical Center, Dallas, Texas; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TexasDepartment of Radiation Oncology, University of Texas, Southwestern Medical Center, Dallas, Texas; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, Texas; Corresponding author: Raquibul Hannan, MD, PhDPurpose: Symptom management is an integral component of care for patients with renal cell carcinoma (RCC). We evaluated the efficacy of radiation therapy (RT) and factors influencing symptom in an ethnically diverse patient population. Methods and Materials: An institutional review board-approved retrospective review was conducted of patients with symptomatic extracranial RCC metastases treated with RT between 2011 and 2022 at a tertiary referral center. Symptoms were categorized as pain, neurologic (paresthesia or weakness), respiratory (dyspnea, hemoptysis, or cough) and gastrointestinal/genitourinary (GI/GU) bleeding. Time to symptom alleviation was measured from the start of RT and assessed during-treatment and follow-up visits. Descriptive and survival analyses were performed. Associations between symptom relief and treatment parameters were evaluated by generalized estimating equations Results: We identified 240 symptomatic RCC patients who received RT to 581 metastases including 93.0% for pain, 4.0% for neurologic, 4.1% for respiratory, and 1.6% for GI/GU bleeding. Symptom improvement was observed in 84.0% of patients overall at 6 months (95% confidence interval [CI], 80.4-87.2%). Among symptom categories, pain improved in 84.6% (95% CI, 81.0-87.9%) at 6 months, respiratory symptoms in 69.9% (49.3-88.0%) at 6 months, neurologic symptoms in 88.6% (69.6-98.1%) at 6 months, and GI/GU bleeding in 37.5% (13.9-77.1%) at 1 month. The median times to overall and pain alleviation were 1.6 months (range, 1.4-1.9) and 1.6 months (range, 1.4-1.9), respectively. Although the odds of achieving pain palliation were similar between stereotactic and conventional RT, unexpectedly, symptom relief occurred more quickly with conventional RT (P < .001). Conclusions: Stereotactic and conventional RT are effective for symptom palliation for patients with metastatic RCC.http://www.sciencedirect.com/science/article/pii/S2452109425001575 |
| spellingShingle | Young Suk Kwon, MD, MPH Eric Hsu, MD, PhD Maggie Stein, BSPH Alana Christie, MS Aurelie Garant, MD Neil B. Desai, MD Andrew Wang, MD Daniel X. Yang, MD Allen Yen, MD Mihailo Miljanic, MD Kevin D. Courtney, MD, PhD Hans Hammers, MD, PhD Tian Zhang, MD Waddah Arafat, MD Qian Qin, MD Suzanne Cole, MD James Brugarolas, MD, PhD Robert Timmerman, MD Raquibul Hannan, MD, PhD Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma Advances in Radiation Oncology |
| title | Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma |
| title_full | Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma |
| title_fullStr | Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma |
| title_full_unstemmed | Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma |
| title_short | Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma |
| title_sort | extracranial palliative radiation therapy for renal cell carcinoma |
| url | http://www.sciencedirect.com/science/article/pii/S2452109425001575 |
| work_keys_str_mv | AT youngsukkwonmdmph extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT erichsumdphd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT maggiesteinbsph extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT alanachristiems extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT aureliegarantmd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT neilbdesaimd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT andrewwangmd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT danielxyangmd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT allenyenmd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT mihailomiljanicmd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT kevindcourtneymdphd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT hanshammersmdphd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT tianzhangmd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT waddaharafatmd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT qianqinmd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT suzannecolemd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT jamesbrugarolasmdphd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT roberttimmermanmd extracranialpalliativeradiationtherapyforrenalcellcarcinoma AT raquibulhannanmdphd extracranialpalliativeradiationtherapyforrenalcellcarcinoma |